Day: January 21, 2025

CALGARY, Alberta, Jan. 20, 2025 (GLOBE NEWSWIRE) — Cielo Waste Solutions Corp. (TSXV:CMC; OTC PINK:CWSFF) (“Cielo” or the “Company”) announces the anticipated settlement of an aggregate $1,622.413.10 (the “Aggregate Debt Amount”) in debt by way of share issuance (each a “Shares for Debt Transaction”, collectively the “Shares for Debt Transactions”), subject to the approval of the TSX Venture Exchange (the “Exchange”). The Company intends to issue a total of 15,451,545 (subject to rounding) common shares (the “Repayment Shares”) at a price of $0.105 per share. The Company has executed agreements with certain of its creditors to issue 14,480,856 of the Repayment Shares at a price of $0.105 per share to settle $1,520,490.67 of the Aggregate Debt Amount. In addition, Cielo intends to execute an agreement on the same or substantially...

WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc’s website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter...

Streamlined organization and Provider Services segment to optimize resource allocation Provider Services focus on Home Health/Hospice, Personal Care, Rehabilitation Services, and Care Management strategic priorities Proceeds from the sale will be used to reduce debt resulting in accelerated deleveraging while also increasing capital availability Divesture expected to increase Company Revenue and EBITDA Growth Rates and Cash Conversion, as well as Provider Services Revenue and EBITDA Growth Rates and Margin1 Company reports 2024 preliminary Revenue and Adjusted EBITDA, above prior guidance issued on November 1, 2024, and initiates 2025 guidance excluding Community LivingLOUISVILLE, Ky., Jan. 20, 2025 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home...